Showing 161 - 180 results of 52,559 for search '(((( 50 a decrease ) OR ( 5 ((we decrease) OR (mean decrease)) ))) OR ( 5 non decrease ))', query time: 0.93s Refine Results
  1. 161
  2. 162
  3. 163
  4. 164
  5. 165
  6. 166
  7. 167
  8. 168
  9. 169
  10. 170
  11. 171
  12. 172
  13. 173
  14. 174
  15. 175

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  16. 176
  17. 177
  18. 178

    CM-DWM-EC chart using 30% decrease in the mean for the E(KeV). by Shumaila Nisar (20114256)

    Published 2024
    “…<p>CM-DWM-EC chart using 30% decrease in the mean for the E(KeV).</p>…”
  19. 179
  20. 180